Source: Annual Congress 2009 - Severe asthma and its treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Somerville, J. Bardelas, A. Viegas, P. D‘Andrea, J. Thirlwell, M. Massanari, G. Peachey (Houston, High Point, East Hanover, United States Of America; West Sussex, United Kingdom). Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma. Eur Respir J 2009; 34: Suppl. 53, 1876

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy and safety of the short term immunotherapy (SIT) in allergic rhinoconjunctivitis (AR) Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005 Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Efficacy and safety of levocetirizine in persistent allergic rhinitis (PER) Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Combination of montelukast and loratadine provides added benefit for relief of symptoms of seasonal allergic rhinitis (SAR) Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004 High doses of omalizumab (OMA) in patients with allergic (IgE-mediated) asthma and IgE/body weight combinations outside the initially approved dosing table Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 The efficacy of desloratadine in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012